Skip to content
Open access

Vitamin D counters bone invasion by mammary cancer through inhibition of inflammation and epithelial-to-mesenchymal transition

Sep 2026 · bioRxiv · 0 citations · 57 references
Biology

TL;DR

It is demonstrated that vitamin D deficiency acts through pro-inflammation factors to help skeletal progression of mammary cancer and provide a strong link between vitamin D deficiency and acceleration of inflammation-driven bone invasion, and nestin and EMT.

Abstract

Vitamin D deficiency is associated with poor outcome in several cancers in humans, and administration of vitamin D or analogs has been shown to decrease tumor progression and metastasis in animal mammary cancer models. We previously demonstrated significant acceleration of carcinogenesis in vitamin D-deficient mouse mammary tumor virus-polyoma middle T (MMTV-PyMT) mammary cancer model as well as of its spontaneous metastasis to lungs. While vitamin D also plays a role in skeletal metastasis, detailed mechanisms of its promotion of bone invasion and metastatic events are not completely elucidated. In the present study we used tibially-injected MMTV-PyMT mammary tumor cells to analyse how dietary-induced vitamin D deficiency in non-immunodeficient FVB mice accelerates bone invasion. Mechanistically, we observed vitamin D deficiency to increase pro-inflammation cytokines and nestin expression in internal bone surface and marrow, and to increase epithelial-to-mesenchymal transition (EMT) through Zeb1 transcription factor. In vitro, treatment of MMTV-PyMT tumor cells with CXCL12 was observed to stimulate Zeb1 expression, and this effect was efficiently countered by 1,25(OH)2D treatment. Analysis of cytokines in MMTV-PyMT mammary tumor cells in vitro showed significant reduction in several pro-inflammatory cytokines with 1,25(OH)2D treatment (GM-CSF, ICAM-1, IL-1ra, IP-10, JE, MCP-5, MIP-1α, MIP-1β, MIP-2, RANTES and CXCL12), a crucial observation in view of the current evidence that inflammation is one of the hallmarks of cancer. Furthermore, vitamin D repleteness is associated with very high expression of Socs1 (suppressor of cytokine signalling 1), an inhibitor of JAK/STAT pathway which prevents excessive inflammatory responses and has a tumor-suppressive role. These findings provide a strong link between vitamin D deficiency and acceleration of inflammation-driven bone invasion, and nestin and EMT. The evidence suggests that vitamin D-repleteness in breast cancer patients could enhance the efficacy of co-administered therapies in preventing invasion of skeletal sites. LAY SUMMARY Vitamin D deficiency, a very common occurrence in the modern world, is associated with poor outcome for several cancers among which colorectal, breast, kidney and thyroid. We previously showed that a vitamin D-deficient diet caused significant acceleration of carcinogenesis and lung metastasis in mouse. Vitamin D also plays a role in skeletal metastasis, however, mechanisms are not yet elucidated. Here, we demonstrate that vitamin D deficiency acts through pro-inflammation factors to help skeletal progression of mammary cancer. Evidence suggests that adequate vitamin D status in breast cancer patients could enhance efficacy of co-administered therapies in preventing deadly invasion of bone.

Read PDF

Similar papers

Open access Sep 2026

Extracellular vesicle-mediated preconditioning of osteoblasts by ER+ breast cancer cells: implications for the bone metastatic niche

Breast cancer metastasis to bone most commonly occurs in late-stage disease and remains a major contributor to morbidity, reduced quality of life, and mortality, particularly in estrogen receptor-positive (ER+) tumors. Intercellular communication between tumor cells and bone-resident cells plays a critical role in prom...

D. Johnson, Edward Shangin, Hannah L. Marrone et al. · 0 citations
Open access Oct 2026

PTHrP induces breast cancer bone metastases via microbial-dependent expansion of TNF/IL-17-producing T cells.

Bone metastases are a frequent complication of breast cancer, leading to reduced quality of life and increased morbidity. By intratibially injecting PyMT breast cancer cells in mice, we showed that the presence in the gut microbiome of segmented filamentous bacteria (SFB), a taxon that induces IL-17-producing Th17 cell...

N. K. Roy, Subhashis Pal, Hamid Y. Dar et al. · 0 citations
Open access Sep 2026

Loss of short-form Ron promotes B and T cell cooperation to prevent outgrowth of breast cancer bone metastasis

While immunotherapy has great potential to eradicate tumors, success in metastatic breast cancer is limited. Bone metastasis, the most common site for breast cancer metastasis, has been associated with weakened anti-tumor immunity, both in the bone and in other metastatic sites. Additional strategies promoting anti-tum...

Clint H. Valencia, Marija S. Nadjsombati, T. Phạm et al. · 0 citations
Open access Sep 2026

Intratumoral Administration of Recombinant Murine Interleukin-12 Prevents Tumor Progression and Bone Invasion.

Intratumoral injection of recombinant murine IL-12 (r-mIL-12) significantly prolonged mouse survival and suppressed tumor growth in immunocompetent mice, suggesting that local administration of r-mIL-12 may serve as an effective therapeutic approach for OSCC with mandibular bone invasion.

S. Kasahara, Miki Kashiwagi, Toshihiro Inubushi et al. · 0 citations
Review Sep 2026

Bone metastasis in cancer: from microenvironmental remodeling to precision therapy.

Bone metastasis remains a major determinant of disability, treatment failure, and poor survival in solid tumors. It is no longer adequately explained as a late consequence of tumor spread or as a process driven only by osteoclast-mediated bone destruction. Current evidence supports a broader view in which bone metastas...

Qin-Gan Feng, Xiu-Hai Ji, Qi Sun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.